BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38066907)

  • 1. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
    Major A; Kamdar M
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):370-381. PubMed ID: 38066907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
    Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
    Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
    Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Gao J; Dahiya S; Patel SA
    Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
    Boyle S; Roddie C; O'Reilly M; Menne T; Norman J; Gibb A; Lugthart S; Chaganti S; Gonzalez Arias C; Jones C; Latif A; Uttenthal BJ; Seymour F; Osborne W; Springell D; Hardefeldt P; Yallop D; Thoulouli E; Bloor A; Besley C; Mathew A; Burns D; Cwynarski K; Sanderson R; Kuhnl A
    Br J Haematol; 2024 Feb; 204(2):507-513. PubMed ID: 37848384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T cell therapy for B-cell lymphomas.
    Chavez JC; Locke FL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
    St-Pierre F; Gordon LI
    Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 17. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
    Johnson PC; Abramson JS
    Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
    Hammons L; Haider S; Portuguese AJ; Banerjee R; Szabo A; Pasquini M; Chhabra S; Radhakrishnan S; Mohan M; Narra R; Dong J; Janz S; Shah NN; Hamadani M; D'Souza A; Hari P; Dhakal B
    Br J Haematol; 2024 Mar; 204(3):887-891. PubMed ID: 38054558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.